Jushi (JUSHF) versus Its Rivals Financial Survey

Jushi (OTCMKTS:JUSHF) is one of 55 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its competitors? We will compare Jushi to similar businesses based on the strength of its profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Profitability

This table compares Jushi and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jushi	-24.16%	-320.66%	-10.31%
Jushi Competitors	-45.53%	-60.43%	-9.08%

Analyst Recommendations

This is a breakdown of current ratings for Jushi and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jushi	0	2	0	0	2.00
Jushi Competitors	246	546	920	66	2.45

As a group, “Medicinals & botanicals” companies have a potential upside of 74.79%. Given Jushi’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Jushi has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

21.7% of Jushi shares are held by institutional investors. Comparatively, 16.1% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 21.0% of Jushi shares are held by company insiders. Comparatively, 22.4% of shares of all “Medicinals & botanicals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Jushi and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Jushi	$269.45 million	-$65.10 million	-2.03
Jushi Competitors	$298.06 million	-$154.30 million	-10.35

Jushi’s competitors have higher revenue, but lower earnings than Jushi. Jushi is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Jushi has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500. Comparatively, Jushi’s competitors have a beta of 1.36, meaning that their average stock price is 36% more volatile than the S&P 500.

Summary

Jushi competitors beat Jushi on 9 of the 13 factors compared.

Jushi Company Profile

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of medical and adult-use products. It focuses on building a portfolio of cannabis assets in various jurisdictions in Pennsylvania, Virginia, Ohio, Illinois, California, Nevada, and Massachusetts. The company also offers hemp-based CBD products, including cannabis dry flower, vaporizer forms of cannabis, edibles, cannabis oil in capsules, tinctures, cannabis in topical products, and other cannabis products, as well as vape cartridges, disposables, and concentrates under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. In addition, it operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. The company is headquartered in Boca Raton, Florida.